Noora (vaccine)

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 09:07, 27 September 2021 (Alter: title. | Use this bot. Report bugs. | Suggested by Anas1712 | Category:Iranian COVID-19 vaccines | #UCB_Category 1/6). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Noora (vaccine)
Vaccine description
TargetSARS-CoV-2
Vaccine typeProtein subunit
Clinical data
Routes of
administration
Intramuscular

Noora is a COVID-19 vaccine candidate developed by Baqiyatallah University of Medical Sciences in Iran.[1][2]

Medical uses

It requiring three doses given by intramuscular injection on days 0, 21 and 35.[3]

Pharmacology

Noora is a recombinant RBD protein subunit vaccine.[3]

Clinical trials

Clinical trials of Noora
Phase Registration number Start Number of participants Age of participants Ref
Total Vaccine Placebo
I IRCT20210620051639N1 25 June 2021 70 30 (80 µg)

30 (120 µg)

10 (placebo) 18–50 years [3]

References

  1. ^ "IRGC starts clinical trial of "Noora" coronavirus vaccine". Tehran Times. 27 June 2021. Retrieved 1 July 2021.
  2. ^ "IRGC Commander: Iran-Made 'Noora' Coronavirus Vaccine Ready for 2nd Stage of Human Trial". Fars News Agency. 22 August 2021. Retrieved 30 August 2021.
  3. ^ a b c "A randomized, double-blinded, placebo-controlled phase I clinical trial to evaluate the safety and immunogenicity of three dose regimens of COVID-19 RBD protein recombinant vaccine (AmitisGen; 80µg and 120µg) in a healthy population". Iranian Clinical Trials Registry. 25 June 2021. IRCT20210620051639N1. Retrieved 1 July 2021.